Pharma-Schwarz

Schwarz Pharma was a prominent German pharmaceutical company focused on developing innovative treatments for the central nervous system (CNS), cardiovascular, and gastrointestinal disorders. The company gained significant recognition for its advanced drug delivery technologies, particularly transdermal patches, and its robust late-stage pipeline. Key products developed by the company include Neupro for Parkinson's disease, Vimpat for epilepsy, and Toviaz for overactive bladder. In 2006, Schwarz Pharma was acquired by UCB for approximately $5.6 billion, a move that transformed UCB into a global leader in neurology. The integration of Schwarz Pharma's R&D and commercial assets provided the foundation for several of UCB's current core products.